Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib with Chemoradiation in Resectable Gastric Cancer
NCT00237900Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Jul 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in gastric cancer (GC), sponsored by AstraZeneca. Started Jul 2003; status: terminated.
02
Drugs
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00237900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00237900.